Acute precipitants of congestive heart failure exacerbations
- PMID: 11606149
- DOI: 10.1001/archinte.161.19.2337
Acute precipitants of congestive heart failure exacerbations
Abstract
Background: Few studies have prospectively and systematically explored the factors that acutely precipitate exacerbation of congestive heart failure (CHF) in patients with left ventricular dysfunction. Knowledge of such factors is important in designing measures to prevent deterioration of clinical status. The objective of this study was to prospectively describe the precipitants associated with exacerbation of CHF status in patients enrolled in the Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study.
Methods: We conducted a 2-stage, multicenter, randomized trial in 768 patients with CHF who had an ejection fraction of less than 40%. Patients were randomly assigned to receive enalapril maleate, candesartan cilexetil, or both for 17 weeks, followed by randomization to receive metoprolol succinate or placebo for 26 weeks. Investigators systematically documented information on clinical presentation, management, and factors associated with the exacerbation for any episode of acute CHF during follow-up.
Results: A total of 323 episodes of worsening of CHF occurred in 180 patients during 43 weeks of follow-up; 143 patients required hospitalization, and 5 died. Factors implicated in worsening of CHF status included noncompliance with salt restriction (22%); other noncardiac causes (20%), notably pulmonary infectious processes; study medications (15%); use of antiarrhythmic agents in the past 48 hours (15%); arrhythmias (13%); calcium channel blockers (13%); and inappropriate reductions in CHF therapy (10%).
Conclusions: A variety of factors, many of which are avoidable, are associated with exacerbation of CHF. Attention to these factors and patient education are important in the prevention of CHF deterioration.
Similar articles
-
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.Am Heart J. 2000 Apr;139(4):609-17. doi: 10.1016/s0002-8703(00)90037-1. Am Heart J. 2000. PMID: 10740141 Clinical Trial.
-
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16. Circulation. 2021. PMID: 33993702 Free PMC article. Clinical Trial.
-
Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.Circulation. 1999 Nov 30;100(22):2224-30. doi: 10.1161/01.cir.100.22.2224. Circulation. 1999. PMID: 10577995 Clinical Trial.
-
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.Can J Cardiol. 1997 Dec;13(12):1166-74. Can J Cardiol. 1997. PMID: 9444298 Review.
-
Candesartan cilexetil: a pharmacoeconomic review of its use in chronic heart failure and hypertension.Pharmacoeconomics. 2006;24(12):1249-72. doi: 10.2165/00019053-200624120-00008. Pharmacoeconomics. 2006. PMID: 17129078 Review.
Cited by
-
Association of a device-based remote management heart failure pathway with outcomes: TriageHF Plus real-world evaluation.ESC Heart Fail. 2024 Oct;11(5):2637-2647. doi: 10.1002/ehf2.14821. Epub 2024 May 7. ESC Heart Fail. 2024. PMID: 38712903 Free PMC article.
-
Acute Heart Failure: From The Emergency Department to the Intensive Care Unit.Cardiol Clin. 2024 May;42(2):165-186. doi: 10.1016/j.ccl.2024.02.005. Epub 2024 Mar 15. Cardiol Clin. 2024. PMID: 38631788 Review.
-
Atrial Flutter in the Elderly Patient: The Growing Role of Ablation in Treatment.Cureus. 2023 Dec 7;15(12):e50096. doi: 10.7759/cureus.50096. eCollection 2023 Dec. Cureus. 2023. PMID: 38186540 Free PMC article.
-
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure.Int J Heart Fail. 2023 Jul 13;5(3):127-145. doi: 10.36628/ijhf.2023.0016. eCollection 2023 Jul. Int J Heart Fail. 2023. PMID: 37554691 Free PMC article. Review.
-
Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure.Korean Circ J. 2023 Jul;53(7):425-451. doi: 10.4070/kcj.2023.0114. Korean Circ J. 2023. PMID: 37525389 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
